This is an interesting analysis to compare induction of remission and other measures of treatment response among patients with moderate-severe ulcerative colitis, comparing treatment with of infliximab and golimumab. Any observation of treatment response will depend upon the frequency of follow-up during the clinical trials. It would help to provide a bit more detail as to how this will be handled (particularly if the trials use different periods of follow-up: ie, q4weeks vs q6weeks, etc). Moreover, I was surprised that the investigators are not taking advantage of time-to-event analyses, as opposed to using multivariable logistic regression, given the study question. Was there a particular reason why not? Hopefully, addressing these aspects of the proposal will strengthen the investigation.